Literature DB >> 30497882

PD-L1 Antibody Comparison in Urothelial Carcinoma.

Maud Rijnders1, Astrid A M van der Veldt2, Tahlita C M Zuiverloon3, Katrien Grünberg4, Erik Thunnissen5, Ronald de Wit6, Geert J L H van Leenders7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30497882     DOI： 10.1016/j.eururo.2018.11.002

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  14 in total

1.  PD-L1 testing in urothelial carcinoma: are we there yet?

Authors:  Geert J L H van Leenders
Journal:  Transl Androl Urol       Date:  2019-12

2.  New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?

Authors:  Markus Eckstein; Shilpa Gupta
Journal:  Ann Transl Med       Date:  2019-07

Review 3.  [Immunological biomarker research in uro-oncology-using the example of urothelial cancer].

Authors:  Markus Eckstein
Journal:  Urologie       Date:  2022-05-30

4.  PD-L1 testing in urothelial bladder cancer: essentials of clinical practice.

Authors:  Julien Adam; Yves Allory; Mathieu Rouanne; Camélia Radulescu
Journal:  World J Urol       Date:  2020-11-03       Impact factor: 4.226

Review 5.  Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation.

Authors:  Kyu Sang Lee; Gheeyoung Choe
Journal:  J Pathol Transl Med       Date:  2021-04-07

Review 6.  Targeting the Immune system and Epigenetic Landscape of Urological Tumors.

Authors:  João Lobo; Carmen Jerónimo; Rui Henrique
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

7.  PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype.

Authors:  Bohyun Kim; Cheol Lee; Young A Kim; Kyung Chul Moon
Journal:  Front Oncol       Date:  2020-12-07       Impact factor: 6.244

Review 8.  Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.

Authors:  Antonio Lopez-Beltran; Alessia Cimadamore; Ana Blanca; Francesco Massari; Nuno Vau; Marina Scarpelli; Liang Cheng; Rodolfo Montironi
Journal:  Cancers (Basel)       Date:  2021-01-03       Impact factor: 6.639

9.  Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer.

Authors:  Megan M Tu; Terry L Ng; Florus C De Jong; Tahlita C M Zuiverloon; Francesco G T Fazzari; Dan Theodorescu
Journal:  Bladder Cancer       Date:  2019-08-16

10.  Prognostic Value of Programmed Death Ligand-1 Expression on Tumor-Infiltrating Immune Cells in Patients Treated with Cisplatin-Based Combination Adjuvant Chemotherapy Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study.

Authors:  Dong Hyeon Lee; Jae Yong Jeong; Wan Song
Journal:  Onco Targets Ther       Date:  2021-02-05       Impact factor: 4.147
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.